Novartis sees 2019 growth as it sheds eyecare unit, narrows focus

ZURICH (Reuters) - Swiss drugmaker Novartis sees mid-single-digit sales growth from its core businesses in 2019 as it sheds its Alcon eyecare unit and a U.S. generics pills business to focus on newer high-tech drugs.

ZURICH (Reuters) - Swiss drugmaker Novartis sees mid-single-digit sales growth from its core businesses in 2019 as it sheds its Alcon eyecare unit and a U.S. generics pills business to focus on newer high-tech drugs. http://bit.ly/2HBIKAh January 29, 2019 at 08:39PM